Exenatide preserves trabecular bone microarchitecture in experimental ovariectomized rat model

被引：13

作者：

Eminov, Elmin ^{[2
]}

Hortu, Ismet ^{[1
]}

Akman, Levent ^{[1
]}

Erbas, Oytun ^{[3
]}

Yavasoglu, Altug ^{[4
]}

Cirpan, Teksin ^{[1
]}

机构：

[1] Ege Univ, Sch Med, Dept Obstet & Gynecol, Izmir, Turkey

[2] Izmir Bornova Turkan Ozilhan State Hosp, Dept Obstet & Gynecol, Izmir, Turkey

[3] Istanbul Bilim Univ, Sch Med, Dept Physiol, Istanbul, Turkey

[4] Ege Univ, Sch Med, Dept Histol & Embryol, Izmir, Turkey

来源：

ARCHIVES OF GYNECOLOGY AND OBSTETRICS | 2018年 / 297卷 / 06期

关键词：

Osteoporosis; Postmenopause; Glucagon-like peptide; Exenatide; GLUCAGON-LIKE PEPTIDE-1; VERTEBRAL FRACTURES; RECEPTOR; MEN; HISTOMORPHOMETRY; OSTEOPOROSIS; RELEASE; WOMEN; GENE; MASS;

D O I：

10.1007/s00404-018-4776-7

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Purpose The aim of this study is to investigate effects of exenatide (Glucagon-Like Peptide Agonist) replacement on bone mineral density (BMD) and microarchitecture in a surgical menopause-induced osteoporosis model in rats. Methods In this study, 24 female Sprague-Dawley albino mature rats were used. Rats were assigned either to the group ovariectomized administered exenatide or to the control group. Bone Mineral Density (BMD), plasma cytokine levels and histomorphometric analysis were measured. Results Ovariectomized rats showed significant decrease BMD values, trabecular counts, trabecular thickness and trabecular area. Also, significant increase trabecular separation and plasma TNE-oc (Tumor Necrosis Factor) and IL-6 (Interleukin) levels. Exenatide treatment reversed these changes and it showed a considerable protective effect on trabecular bone microarchitecture. Conclusions Exenatide may be a candidate for use in the treatment of postmenopausal osteoporosis and anti-inflammatory properties can be attributed this effects.

引用

页码：1587 / 1593

页数：7

共 31 条

[1] Bone microarchitecture and bone fragility in men:: DXA and histomorphometry in humans and in the orchidectomized rat model [J].

Audran, M ;

Chappard, D ;

Legrand, E ;

Libouban, H ;

Baslé, MF .

CALCIFIED TISSUE INTERNATIONAL, 2001, 69 (04) :214-217

[2]

Bagi CM, 1996, ANAT REC, V245, P633

[3] Bone microarchitecture evaluated by histomorphometry [J].

Carbonare, LD ;

Valenti, MT ;

Bertoldo, F ;

Zanatta, M ;

Zenari, S ;

Realdi, G ;

Lo Cascio, V ;

Giannini, S .

MICRON, 2005, 36 (7-8) :609-616

[4] Mortality after all major types of osteoporotic fracture in men and women: an observational study [J].

Center, JR ;

Nguyen, TV ;

Schneider, D ;

Sambrook, PN ;

Eisman, JA .

LANCET, 1999, 353 (9156) :878-882

[5] Exenatide Exerts a Potent Antiinflammatory Effect [J].

Chaudhuri, Ajay ;

Ghanim, Husam ;

Vora, Mehul ;

Sia, Chang Ling ;

Korzeniewski, Kelly ;

Dhindsa, Sandeep ;

Makdissi, Antoine ;

Dandona, Paresh .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (01) :198-207

[6]

Choi Hee-Jeong, 2015, J Menopausal Med, V21, P1, DOI 10.6118/jmm.2015.21.1.1

[7] Clinical use of bone densitometry - Scientific review [J].

Cummings, SR ;

Bates, D ;

Black, DM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (15) :1889-1897

[8] Role of biochemical markers in the management of osteoporosis [J].

Ebeling, PR .

BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2001, 15 (03) :385-400

[9] Role of gastrointestinal hormones in postprandial reduction of bone resorption [J].

Henriksen, DB ;

Alexandersen, P ;

Bjarnason, NH ;

Vilsboll, T ;

Hartmann, B ;

Henriksen, EEG ;

Byrjalsen, I ;

Krarup, T ;

Holst, JJ ;

Christiansen, C .

JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 (12) :2180-2189

[10] Four-month treatment with GLP-2 significantly increases hip BMD A randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD [J].

Henriksen, Dennis B. ;

Alexandersen, Peter ;

Hartmann, Bolette ;

Adrian, Charlotte L. ;

Byrjalsen, Inger ;

Bone, Henry G. ;

Holst, Jens J. ;

Christiansen, Claus .

BONE, 2009, 45 (05) :833-842

← 1 2 3 4 →